STO · ADDV-B.ST
ADDvise Group AB (publ)
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
Loading market information…
STO · FLUO.ST · SEK
Stock price, earnings
Quote as of Oct 29, 2026, 03:42 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
FluoGuide A/S’s quoted price sits in the lower half of its reported 52-week range, 34.1% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
FluoGuide A/S’s next earnings report is currently expected on Nov 26, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow FluoGuide A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
SEK 0.47-SEK 0.01 (-2.08%)
Doxa AB’s quoted price sits in the upper half of its reported 52-week range, 14.55% below the high.
SEK 2.13-SEK 0.02 (-0.93%)
Enzymatica AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 37.35% below the high.
SEK 10.94-SEK 0.08 (-0.73%)
Moberg Pharma AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 22.52% below the high.
SEK 16.00-SEK 0.10 (-0.62%)
Bactiguard Holding AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 25.93% below the high.
SEK 14.30+SEK 0.20 (+1.42%)
Corline Biomedical AB’s quoted price sits in the lower half of its reported 52-week range, 29.21% below the high.
SEK 5.17-SEK 0.17 (-3.18%)
Mendus AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 39.1% below the high.
SEK 0.28-SEK 0.01 (-3.81%)
iZafe Group AB’s quoted price sits in the lower half of its reported 52-week range, 65.25% below the high.
